SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-24-029050
Filing Date
2024-06-06
Accepted
2024-06-06 06:01:23
Documents
16
Period of Report
2024-06-04
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20030678_8k.htm   iXBRL 8-K 28042
2 EXHIBIT 99.1 ef20030678_ex99-1.htm EX-99.1 23543
6 image2.jpg GRAPHIC 663
7 image3.jpg GRAPHIC 691
  Complete submission text file 0001140361-24-029050.txt   199394

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bbio-20240604.xsd EX-101.SCH 3868
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20240604_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20240604_pre.xml EX-101.PRE 16046
19 EXTRACTED XBRL INSTANCE DOCUMENT ef20030678_8k_htm.xml XML 4225
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 241023765
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)